Entities

Neurogene chief scientific officer, leading scientific research and strategy since joining in 2019. A translational neuroscientist who also leads research at the University of Edinburgh, with earlier work at Glasgow. Holds a Glasgow BSc and Oxford neuroscience PhD.

Clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its EXACT platform uses microRNA-based circuits to regulate transgene expression and address overexpression toxicity. Its lead investigational AAV gene therapy, NGN-401 for Rett syndrome, is being evaluated in the Embolden registrational trial. It operates an in-house gene therapy manufacturing facility in Houston and became publicly traded on Nasdaq as NGNE following its December 2023 reverse merger with Neoleukin Therapeutics.

President and chief financial officer of Neurogene and a board director, leading corporate strategy, business development, portfolio management, operations and finance. Joined Neurogene in 2019. Previously chief administrative officer, external business development leader and general counsel at Axovant Sciences. Holds Rutgers and Fordham law degrees.

Founder and chief executive officer of Neurogene and executive chair of its board. Founded the neurological gene therapy company in January 2018. Previously chief business and strategy officer at Intercept Pharmaceuticals and a biotechnology analyst. Holds a Cornell bachelor's degree and a Scripps Research Institute PhD, followed by a Berkeley Miller fellowship.

Medical-device entrepreneur and RiverVest consultant/venture partner in Tel Aviv. Former president of Boston Scientific’s cardiology business and a co-founder of multiple medical technology companies, including Velocimed; distinct from the Tectonic co-founder Michael Berman.

American Century Private Investments is American Century Investments’ venture capital investment unit, led by the former 3x5 Partners team. It backs early-stage healthcare and environmental technologies, including medical devices, diagnostics, biopharmaceuticals, drug delivery, life science tools, clean energy, water, sustainable materials, agriculture and waste reduction. Its investors work with founders and company executives to develop technologies addressing human health and environmental needs. It is a business unit within the broader asset manager, rather than a separate public-market fund.

503 Partners, formerly 3x5 Partners, is a Portland venture investment adviser focused on healthcare and resource-driven technologies such as water, energy, agriculture and sustainable materials. Its investment team joined American Century Investments in 2023 to build that manager’s private investment unit, while 503 Partners continues to report legacy investment vehicles and legal managers in its regulatory filings. Historical investments under the 3x5 name include Bonum Therapeutics, Good Therapeutics and Fervo Energy. Its retained 3x5 logo represents the historical brand.

EcoR1 senior analyst evaluating biotechnology investments. Previously advised biotechnology clients on acquisitions and equity offerings at Goldman Sachs. Holds a Harvard neurobiology degree.

EcoR1 chief financial officer overseeing firm and fund accounting and finance. Previously worked at Sheffield Asset Management, Grosvenor Capital Management, Bank of America and Sunrise Capital Partners. Holds an Illinois finance degree.

EcoR1 analyst evaluating biotechnology investments. Previously led a venture-backed biotechnology company. Holds a UCSF PhD and UC Berkeley studies in bioengineering, electrical engineering and computer science.

EcoR1 controller overseeing fund and firm accounting and finance. Previously worked at Agile Fund Solutions and Kaufman Rossin Fund Services. Holds a Ulyanovsk State University finance degree.

EcoR1 partner, chief operating officer, general counsel and chief compliance officer responsible for operations, legal and compliance. Previously worked as a prosecutor and at Orrick and clerked at the Tenth Circuit. Holds a Berkeley law degree and Amherst bachelor's degree.

EcoR1 operations manager responsible for office administration and operations. Previously worked at the American Heart Association. Holds a College of Charleston finance degree.

EcoR1 trader, previously a trader at Castle Hook Partners. Holds a Syracuse economics degree.

EcoR1 investor relations associate. Previously advised biotechnology and pharmaceutical companies at Stern Investor Relations and worked with hospital systems at Cloudmed. Holds a UCLA human biology and society degree.

EcoR1 counsel responsible for legal and compliance matters. Previously worked as a litigation associate. Holds a UCLA law degree and University of Iowa English degree.

EcoR1 executive personal assistant to partner Caroline Stout, with prior financial services executive support experience. Holds a UCLA Asian American studies degree.

EcoR1 partner investing in biotechnology. Previously worked in investment banking at Credit Suisse and served as chief investment officer of Panacea Acquisition Corp I and II. Holds a Georgetown economics degree with pre-medical study and a cognitive science minor.

EcoR1 analyst evaluating biotechnology investment opportunities. Previously advised pharmaceutical and biotech companies on acquisitions and equity offerings at BofA Securities. Holds a Stanford economics degree.

EcoR1 principal evaluating biotechnology investments. Previously worked at Brace Pharma Capital. Holds a Virginia Tech biology degree and Georgetown biotechnology master's degree.

San Francisco biotechnology investment advisory firm founded by Oleg Nodelman. It invests in companies across stages of research and development, combining scientific evaluation with investment analysis. Its published venture portfolio includes AI-enabled drug discovery, computational biotechnology, cell and gene therapies, and companies developing treatments for neurological disorders.

EcoR1 analyst evaluating biotechnology investment opportunities. Previously advised pharmaceutical and biotechnology companies at Deloitte. Holds natural sciences degrees with a chemistry specialization from Cambridge.

EcoR1 Capital founder and portfolio manager, establishing the biotechnology investment firm in 2013. Previously managed investments at BVF Partners. Holds a Georgetown science and technology-focused foreign service degree.

Bonum Therapeutics develops dual-binding antibody medicines whose therapeutic activity switches on when a sensor binds a specified target and switches off when the molecule disengages. It uses this reversible regulation to concentrate cytokine activity in tumors and reduce effects elsewhere in the body. Its initial programs target cancer, with potential applications in autoimmune disease, metabolic disorders and pain. Bonum continued the team and retained platform of Good Therapeutics after Roche acquired that predecessor’s PD-1-regulated IL-2 program in 2022; the companies and financings are distinct.

Monique Schiersing is a Senior Investment Director at Roche Venture Fund. Bonum’s primary biography documents earlier RVF work during2009–2018, a period as Inthera Bioscience chief operating officer and investment experience at BankInvest. She also worked in Roche pharmaceutical business development. Holds a microbiology MSc from Zurich and an MBA from the University of San Francisco. Her existing Bonum board role is preserved; no personal cash investment is inferred.

Sam Blackman is published by GV as Entrepreneur in Residence. A physician-scientist and pediatric neuro-oncologist working as entrepreneur in residence. Co-founded Day One Biopharmaceuticals and previously led its medical and drug-development organization.

Aulis Capital invests in early and growth-stage healthcare companies, including biotechnology, medical devices, diagnostics and digital health. It combines scientific and investment expertise with partnerships across Asia and global healthcare markets to help companies develop therapies, validate products, and expand internationally. Its published team includes healthcare investors and operating specialists, and its investments include EpiBiologics’ extracellular protein-degradation platform.

Codon Capital is an early-stage biotechnology investor led by founder and managing partner Karl Handelsman. It backs teams developing differentiated therapeutic technologies and helps scientists and entrepreneurs turn research into companies. Disclosed investments include EpiBiologics’ extracellular protein degradation, Bonum Therapeutics’ conditionally active biologic medicines, Seismic Therapeutic’s machine-learning-assisted immunology programs, and AIRNA’s RNA-editing therapies.

Amir Nashat serves as Director at CAMP4 Therapeutics. CEO of Soufflé Therapeutics and entrepreneur partner at Polaris Partners, where he formerly served as managing partner. Also chairs Dewpoint’s board and has founded and financed biotechnology companies. Current Polaris entrepreneur partner in Boston and managing partner of Funds VI–IX. Joined in2002, is CEO of Soufflé Therapeutics and represents Polaris on healthcare boards, including CAMP4. Current entrepreneur-partner title is retained separately from fund-specific managing-partner responsibilities.

Dewpoint scientific co-founder and board member, also known as Tony Hyman. His research helped establish how phase separation creates biomolecular condensates and investigates their role in cellular organization and neurodegenerative diseases including ALS.

Dewpoint early discovery leader, also known as Avi Patel, studying condensate disease biology and target discovery. His postdoctoral work with Tony Hyman investigated FUS condensates in ALS and the role of ATP in protein solubility and condensation.

Dewpoint head of finance and accounting. Previously led controllership functions at AskBio and Precision BioSciences and worked in corporate finance at MedImmune, Cisco and HP. Began his career as a Deloitte CPA and holds degrees from Babson and Bentley.

Dewpoint board member and drug discovery scientist with experience in antiviral, immunology and biotherapeutics programs. Previously worked at Moderna, AstraZeneca, Boehringer Ingelheim and Pfizer. Holds a University College London biochemistry and molecular biology PhD.

Dewpoint clinical development leader and physician-scientist specializing in oncology and hematology. Previously held development roles at Zai Laboratory, Sanofi and Merck. Holds a University of Pennsylvania medical degree and trained at Johns Hopkins and Beth Israel Deaconess.

Dewpoint board member and structure-based drug design scientist. Co-founded Relay Therapeutics and previously served as Vertex Pharmaceuticals' chief technology officer. Contributed to medicines for HIV, hepatitis C, cystic fibrosis and glaucoma. Holds a Yale organic chemistry PhD.

Dewpoint head of financial planning and analysis. Worked in financial services and healthcare before moving into life sciences, supporting the financial planning needs of drug discovery programs.

Dewpoint board member and pharmaceutical executive. Former chief executive of Sanofi and Bayer HealthCare, with earlier leadership roles at Pfizer. Trained in infectious diseases and tropical medicine and holds biology and cellular immunology qualifications.

Dewpoint board member and MIT professor researching AI and health, natural language processing and deep learning applications in chemistry and oncology. An AI faculty lead at the Jameel Clinic, she holds a Columbia computer science PhD.

Richard Young serves as Director at CAMP4 Therapeutics. CAMP4 scientific co-founder and board director, also known as Rick Young. Whitehead Institute researcher and MIT biology professor studying gene control and cellular regulation; also a scientific founder and director of Dewpoint Therapeutics.

Dewpoint board member and Samsara BioCapital founder and managing general partner. Previously worked at Sofinnova Ventures, New Leaf Venture Partners, Panorama Capital, J.P. Morgan Partners and Genentech. Holds a Stanford medical degree and immunology PhD and Rice biochemistry and computer science degrees. Srinivas Akkaraju is listed by Samsara BioCapital as Founder & Managing Partner. Also known as Srini, he founded the platform after investment roles at Sofinnova, NewLeaf, Panorama and JPMorgan, and corporate-development work at Genentech. His education combines medicine, immunology, biochemistry and computer science.

Dewpoint board member and Leaps by Bayer senior director of venture investments, joining Leaps in 2026. Previously helped launch and lead Dana-Farber's Binney Street Capital and co-founded NextRNA Therapeutics. Holds a Union College mathematics degree and Mayo Clinic immunology PhD.

Dewpoint chief executive and board member, a physician and global drug developer. Previously held chief medical and chief digital officer roles at Sanofi and senior medical affairs and development roles at Novartis. Trained in cardiology and intensive care medicine and holds an MBA.

Dewpoint chief scientific officer leading condensate-based research across oncology, neurology, cardiology and metabolic disease. Her work studies gene control, transcription factor phase separation and drug partitioning into condensates. Holds a Stockholm University biology PhD and trained at the Whitehead Institute.

Dewpoint technology and corporate strategy leader working at the intersection of data science and healthcare R&D. Previously led biopharma AI projects at McKinsey and QuantumBlack and product teams at Genomics England. His PhD research combined computational modelling and experimental neuroscience to study spatial memory.

Dewpoint general counsel, head of corporate affairs and corporate secretary. Previously led the legal function at InVivo Therapeutics and worked on intellectual property and legal matters at Ecolab and PLR IP. Holds biochemistry and chemistry degrees, a law degree and a Harvard management master's degree.

Dewpoint chief development and operating officer, physician-scientist and medical oncologist working on condensate biology and therapeutic development. Previously worked at Dana-Farber, Harvard Medical School and the Whitehead Institute. Holds a Rockefeller immunology and genetics PhD and Weill Cornell medical degree.

EpiBiologics develops bispecific antibodies that selectively remove disease-causing membrane and extracellular proteins. Its EpiTAC platform recruits tissue-specific cell-surface receptors to degrade targets while sparing healthy tissue, with therapeutic programs in oncology and immunology and potential applications in neurological disease. Lead candidate EPI-326 is an investigational EGFR degrader in a Phase 1 solid-tumor study. The company was co-incubated by Mubadala Capital and Polaris Partners from scientific founder Jim Wells’s UCSF research.

Anika Gupta is published by GV as Principal. A biotechnology investor and company builder with a bioinformatics research background. Earlier work included patient-stratification methods at Foundation Medicine and immunotherapy prediction at Merck; her own full name is Anika Gupta Vatsa.

Mitchell Mutz is listed by Samsara BioCapital as Senior Principal. He joined in2025 after investing at Vivo and Roche. He co-founded Amplyx and helped establish Labcyte, bringing chemistry, drug-development and biotechnology entrepreneurship experience.

Rami Hannoush is Versant Ventures’ current Venture Partner. Drug-discovery scientist and company-building venture partner with source-published therapeutic protein and small-molecule research experience. His earlier roles include Mubadala Capital healthcare general partner, EpiBiologics co-founder/CEO and Genentech therapeutic-modality research leadership. He holds a McGill chemistry doctorate and completed Harvard postdoctoral work.

Neural Galaxy co-founder and former president and CEO, also known as Coach Kecheng Wei. Previously co-founded venture-backed technology companies working on enterprise applications, cloud computing and artificial intelligence. Studied at Tsinghua University and MIT. His Neural Galaxy CEO role ended in April 2024 according to a 2026 court order.

Neural Galaxy co-founder and MIT neuroscientist. Director of the McGovern Institute and Doris and Don Berkey Professor in Brain and Cognitive Sciences, studying visual attention and neural communication. Previously directed the National Institute of Mental Health's intramural research program.

Neural Galaxy co-founder and chief scientist researching individualized brain functional architecture, computational neuroimaging and precision neuromodulation. His 2026 research disclosure also identifies him as a co-founder and chief scientist of Galaxy Brain Scientific. His work includes methods for personalized functional circuit mapping and neuromodulation targeting.

Alaa Halawa is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as Executive Director. This is an advisory or cohort network affiliation, rather than a firm employee position.

Founding partner of 3E Bioventures Capital, investing in healthcare and the intersection of medical and information technologies. Previously led healthcare investment at Kaiwu Capital and CRCI Capital, co-founded Shenogen Pharma and worked at McKinsey. Holds a Cornell bachelor's degree, a Harvard Master of Medical Sciences and immunology PhD, and a CKGSB EMBA.

Firstsource Solutions Limited is a business process services and technology company in the RP-Sanjiv Goenka Group. It designs, builds and operates enterprise workflows across healthcare, banking and financial services, communications, technology and other sectors. Its services include customer experience, intelligent back-office processing, collections, consulting, technology implementation and AI data services. The company also makes strategic equity investments in AI technology partners.

Cogzia develops AI software for upstream oil and gas teams to reconcile fragmented operational, reservoir, financial and land data. Its platform analyzes deals, assets, wells and mineral rights, linking conclusions to supporting evidence and integrating with existing tools. The company applies experience building AI for regulated industries to auditable workflows for energy operators and investors.

Myrobalan clinical adviser for neuro-ophthalmology, also known as Yin Allison Liu. UC Davis neuro-ophthalmology researcher studying ocular biomarkers for neurological and neurodegenerative conditions, with training in cancer immunotherapy, child neurology and neuro-ophthalmology.

Craig Fox is listed as Operating Partner, Life Sciences by Oxford Science Enterprises. Current public directory reviewed October7,2026.

Current primary B Capital biography reviewed October8,2026: Karen Page is a General Partner and Board Partner at B Capital. As a Board Partner, she collaborates with portfolio company leadership, B Capital’s investment team and the firm’s network of advisors to provide best-in-class strategic guidance, governance expertise, and hands-on operating support to help companies scale and succeed. At B Capital, she has invested in and/or serves on the board of early-stage and growth companies such as Overstory, Pendo, Clari, Highspot, Centivo, Isaac Health, and Kandji. Prior to joining B Capital, Karen made significant contributions to industry giants like Apple, where she spearheaded the commercial channel, strategic partnerships and key mobility initiatives. As one of the founding executives at Box, she played a pivotal role in shaping the company’s go-to-market strategy, forging partnerships, establishing Box.org and leading the Industry Verticals team. During her tenure, Box grew from zero revenue to over a billion-dollar valuation and successfully went public in 2015. Karen earned a BS from Towson University and an MS in Advanced Behavioral Science and Organizational Development from Johns Hopkins Carey Business School. She is based in San Francisco.

Myrobalan PET imaging adviser and Harvard Medical School radiology researcher at Massachusetts General Hospital. Develops small-molecule PET radioligands and immunoPET approaches for neurological and demyelinating diseases. Holds a University of Chicago chemistry PhD.

Myrobalan clinical adviser for ALS and a neurologist at The Neuro in Montreal. Leads ALS care and research programs and works on clinical trial design for rare neurological and motor neuron diseases. Earned her medical degree at Memorial University of Newfoundland.

Myrobalan scientific adviser and Northwestern University neurology professor. Studies oligodendrocytes, myelin biology and neurological disorders involving demyelination, including multiple sclerosis, to develop approaches to myelin repair.

Myrobalan board adviser with biotechnology leadership, fundraising and public offering experience. Previously led Curis and held business development roles at the Jackson Laboratory and Gene Logic. Holds a George Washington University law degree.

Myrobalan clinical adviser for multiple sclerosis and neuromyelitis optica. Neurologist at Massachusetts General Hospital and Harvard Medical School specializing in neuroimmunology and MS care. Trained at the University of South Dakota and Washington University in St. Louis.

Myrobalan clinical adviser for neuro-ophthalmology and a UC Davis ophthalmology clinician-scientist. Studies retinal diseases, ocular imaging, gene editing and delivery. Holds Harvard MD-PhD degrees, with residency at Massachusetts Eye and Ear and fellowship training at Duke.

Myrobalan clinical adviser for multiple sclerosis and a University of Freiburg neurology professor. Researches inflammatory neurodegeneration, immune regulation and monitoring of MS and its treatment. Previously led neurology at the University of Münster.

Myrobalan scientific adviser and Harvard stem cell and regenerative biology researcher. Studies neurodegeneration, neuromuscular regeneration and brain aging, with translational neuroscience experience in biotechnology and academia. Holds a Rockefeller University neuroscience PhD.

Myrobalan biomarker adviser and translational neuroscience scientist. Worked on neurological drug development at Biogen and Elan and advises on industry-academic collaborations. Holds a Yale molecular biophysics and biochemistry PhD.

Myrobalan board adviser and biotechnology executive. Previously president and CEO of Curis and ACT Biotech, chief scientific officer at Sagres Discovery and a vice president at Onyx Pharmaceuticals. Holds a Kansas State University microbiology PhD.

Myrobalan board adviser and healthcare finance executive. Previously CFO at Constellation Pharmaceuticals, Parexel, Inotek and Aton, with experience in company transformation, public offerings and acquisitions. Its current directory lists an adviser role following a 2024 director appointment.

Myrobalan board adviser and biotechnology executive. Former Epizyme CEO and TESARO chief commercial officer, with earlier leadership experience at Millennium Pharmaceuticals, McKesson, Roche and Knoll. Previously appointed to Myrobalan's board of directors in 2024; its current directory lists him as an adviser.

Myrobalan board member and 3E Bioventures Capital partner. Previously worked in pharmaceutical R&D at Novartis, Roche and GlaxoSmithKline. Holds a Fudan University physics degree and a New York University biochemistry PhD.

Myrobalan board member and managing director at Guanzi Private Equity Fund Management in Hangzhou. Previously a managing director at CICC Capital. Holds a University of Illinois Urbana-Champaign finance MS and a Peking University bachelor's degree.

Myrobalan consultant leading chemistry, manufacturing and controls. Technical operations executive with small-molecule development experience at Curis, Imara and Ziopharm. Holds a Northeastern MBA and a Rochester Institute of Technology chemistry BS.

Myrobalan consultant leading global regulatory strategy. Regulatory and quality executive with experience at Alkermes, Palleon Pharmaceuticals and Biogen, covering small molecules, biologics and gene therapies. Holds a UC Berkeley organic chemistry PhD.

Myrobalan board member and Co-win Ventures managing partner who established its healthcare practice. Previously a BCG consultant and Omaha Capital senior investment manager. Holds a Peking Union Medical College MD and a Johns Hopkins PhD. Distinct from the Curie.Bio structural biology scientist with the same name.

Myrobalan finance director and corporate controller, overseeing finance, accounting and operational matters. Previously worked at Putnam Investments and Poseidon Water. Holds a Suffolk University accounting master's degree and an economics BA from Shanghai University of International Business and Economics.

Myrobalan head of medicinal chemistry, leading chemistry across its portfolio. Previously developed small-molecule programs at Alantos, Hydra Biosciences, Mitobridge and Tango Therapeutics. Holds a SUNY Stony Brook organic chemistry PhD and a Peking University chemistry BS.

Myrobalan fractional chief medical officer and physician-scientist with translational and clinical neuroscience drug development experience. Previously chief medical officer at Cassava Sciences and ProMIS Neurosciences and a neuroscience clinical development leader at Pfizer.

Myrobalan co-founder, CEO and board member. Drug development leader with prior R&D roles at Curis, TESARO/GSK and Constellation. Led translational work on ZEJULA and holds a Harvard Medical School PhD focused on neurodegeneration.

Myrobalan chief scientific officer and neuroscience drug discovery leader. Previously led CNS biology at Alkermes, established translational cellular science capabilities at Biogen and worked on CNS discovery at Pfizer. Holds a University of Virginia neuroscience PhD and completed postdoctoral research at UCSF.

Myrobalan scientific co-founder and board member. MIT neuroscience professor and McGovern Institute researcher studying synaptic modulation and psychiatric disorders. Also works with the Broad Institute and co-founded companies including Rugen, NeuralGalaxy and Emugen.

Medford, Massachusetts biotechnology company developing brain-penetrant oral small-molecule therapies intended to address neuroinflammation and promote myelin repair. Founded by Jing Wang, Zhigang He and Guoping Feng, it pursues neurorestorative approaches for multiple sclerosis, ALS, Alzheimer's disease and other CNS conditions. Its investigational programs target CSF1R, GPR17 and TYK2, with biomarker-guided precision neurology supporting development.

AB Magnitude Ventures Group founding managing director and computational drug discovery scientist. A founding member of D. E. Shaw Research, he helped design the Anton molecular dynamics supercomputer and developed simulation algorithms for structural biology and drug discovery. Holds a computer science master's degree and a biophysics PhD from Drexel University. Also a board member at Myrobalan Therapeutics.

Biotechnology venture investment firm led by computational drug discovery scientist Yibing Shan. It supports scientist founders developing therapeutics and healthcare innovations, including AI-enabled drug discovery, computationally designed oncology medicines and neurorestorative therapies. Public financing sources identify investments in ArrePath, BAKX, Myrobalan, Tasca and Odyssey Therapeutics.

Andrew Cleeland advises ClavystBio and is CEO of Fogarty Innovation. He previously led the medical-device companies Ardian and Twelve, both subsequently acquired by Medtronic, and later led Medtronic’s transcatheter mitral-valve business.

Christopher Eso is listed in Flare Capital Partners’ current public directory as Industry Advisory Board member. The directory describes the external professional affiliation as VP, CSH Strategy, Growth & Business Development Medtronic. This is an advisory or cohort network affiliation, rather than a firm employee position.

Healthcare venture investor listed as an independent director of BioScience Managers. Her published career includes Domain Associates, Rothschild Asset Management, Cephalon and Eastman Kodak investment/corporate-development work. Holds mathematics and finance degrees from Rochester. Outside boards in the older biography are career context rather than independently verified current appointments.

Qoniq, formerly Huma.AI, develops AI software and expert-supported workflows for Medical and Scientific Affairs teams at life science companies. Its platform analyzes scientific literature and other internal and external evidence, helps synthesize findings, and produces source-linked materials such as literature reviews and standard response letters. The company combines tailored analytics with human scientific review and implementation support.

ArrePath board member and Boehringer Ingelheim Venture Fund investment manager in the United States. Joined BIVF in 2026 after a decade of drug discovery and oncology R&D at Boehringer Ingelheim. Holds a biology PhD from the Max Planck Institute for Multidisciplinary Sciences, with postdoctoral research at IMBA in Vienna.

ArrePath board member and Innospark Ventures managing director. Entrepreneur and investor with expertise in AI, natural language understanding and computational algorithms. Founded companies including eCredit, Corporate Fundamentals and Rage Frameworks, and previously taught at Northeastern University. Founder and Managing Director of Innospark Ventures, focused on applied AI and early-stage scientific technology. His entrepreneurial background includes eCredit, Corporate Fundamentals and Rage Frameworks. His primary biography describes AI, natural-language understanding and computational research, a doctorate from the University of Cincinnati and undergraduate study at Delhi University.

ArrePath board chair and physician-scientist with biotechnology company leadership experience. Previously led AZURNA Therapeutics, Laronde and Vividion Therapeutics and held R&D leadership roles at Johnson & Johnson. Earned an MD from the University of Buenos Aires.

ArrePath chief technology officer leading AI/ML strategy and scientific data infrastructure. Built the company's AI/ML platform as its second employee. Previously led data science at Zymergen and directed the Nikon Imaging Center at UCSF. Holds a UCSF biophysics PhD and a Princeton chemistry BA.

ArrePath founder, scientific advisory board chair and board member. Princeton professor of biology and molecular biology researching bacterial cell biology and antibiotic development with quantitative and computational methods. Educated at MIT and UCSF, with postdoctoral research at Stanford.

ArrePath chief scientific officer leading scientific strategy and drug discovery programs. Previously held R&D leadership roles at Entasis Therapeutics and Design Therapeutics, and worked at AstraZeneca, Pfizer, Merck and Eli Lilly. Earned a PhD in biochemistry and molecular biology from the University of Chicago.

ArrePath president, CEO and board member. Previously chief strategy officer at AN2 Therapeutics, with drug development and corporate development experience at Achaogen, Cerexa and Theravance BioPharma. Holds an MBA from UC Berkeley and a BS in cell and molecular biology from San Francisco State.

Princeton biotechnology company using AI, machine learning and experimental chemistry to discover oral small-molecule drugs. Its platform develops target-specific models to optimize activity and developability together. Initially proven in antibacterial discovery, the company is expanding into immunology and inflammation while seeking partners for its legacy antibiotic programs.

Laerdal Million Lives Fund is a healthcare venture investor backing technologies intended to prevent premature deaths and improve access, affordability and quality of care. It invests in data-driven medical technologies and digital tools for early intervention, clinical decisions and safer care delivery. Its portfolio spans emergency response, medical devices, care coordination and global health services.

Pharaoh Neuro develops medical devices for neurocritical care and minimally invasive neurosurgery. Its investigational Neurapheresis system circulates and filters a patient’s cerebrospinal fluid to remove blood and breakdown products after serious neurological injury, including aneurysmal subarachnoid hemorrhage. Its MindsEye expandable cranial access port supports neurosurgical procedures.